Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

FDA advises doctors that a type of laproscopic surgery can spread uterine cancer

Posted: April 19, 2014

Doctors should stop using power morcellators to remove uterine growths, or fibroids, in women’s abdomens because doing so increases the risk of spreading cancer, the Food and Drug Administration (FDA) advised.

Repros enrolls men to test new topical testosterone treatment Androxal

Posted: April 19, 2014

Repros Therapeutics Inc. announced it has completed enrollment for one of two clinical trials pitting its topical testosterone gel alternative Androxal against other topical testosterone products currently on the market.

Many cardiologists reluctant to follow new guidelines for cholesterol-lowering statins

Posted: April 19, 2014

Not all cardiologists agree with or plan to adhere to new guidelines that support more liberal use of cholesterol-lowering statins, such as Lipitor and Zocor, among more populations of patients, according to comments made by cardiologists last week at the

FDA approves new type 2 diabetes drug Tanzeum

Posted: April 18, 2014

After a three-month delay, the Food and Drug Administration (FDA) has approved GlaxoSmithKline’s new type 2 diabetes treatment, albiglutide. The drug will be marketed in the United States as Tanzeum.

Study: Low T contributes to more satisfying relationships

Posted: April 17, 2014

Low testosterone levels in men have been blamed for a variety of symptoms – from low sex drive and mood swings to weight gain and muscle loss. But a new study shows that low testosterone has its benefits. It may actually

Cases of diabetes on the rise in the United States

Posted: April 17, 2014

The number of Americans with diabetes has nearly doubled in the past 20 years, paralleling the country’s growing obesity epidemic. Experts say if the trend continues, the number of Americans with diabetes will reach 44 million in the next 20

Federal judge blocks Massachusetts ban of new painkiller Zohydro

Posted: April 16, 2014

Drug maker Zogenix Inc., won another battle in its war to get its controversial painkiller Zohydro on the market. This week, a Massachusetts federal judge blocked plans by Massachusetts Gov. Deval Patrick to ban prescriptions and sales of the newly

Boys with autism more likely to have been exposed to SSRIs in womb

Posted: April 16, 2014

Boys born to women who took a type of antidepressant during pregnancy were three times more likely to be diagnosed with autism than boys who were not exposed to the drugs in utero, a new study has found. The greatest

Doctor raises red flags regarding heart risks with testosterone therapy

Posted: April 15, 2014

Testosterone replacement therapy may sound attractive with ads promising to build muscle mass and boost libido, but Low T therapy may not be all that it’s cracked up to be, warns Dr. Joe Littlejohn, a urologist at Orlando Health. It

Consumer Reports group pushes for warranties on artificial hips

Posted: April 14, 2014

Nearly a half-million Americans each year undergo hip replacement surgery, an invasive operation that requires weeks of rehabilitation. Typical hip implants can last 20 years or more before being replaced, but some have been shown to fail at a faster